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Objective: Epithelial ovarian cancer is the most lethal gynecologic cancer worldwide and chemo-
resistance is one of the major causes of treatment failure. We investigated whether ERCC1, TAU, TOPO2A,
TOPO1, P53, and C-MYC expression could be used as predictors for treatment outcomes.
Materials and methods: Immunohistochemical staining was used to examine the expression of these
biomarkers in resected tumor specimens from 38 patients treated in our institute. Clinicopathological
data including demographics, staging, histological type, treatment response, expression of the bio-
markers, and patient outcomes were analyzed.
Results: The median follow-up period was 47.5 months (range, 10e135 months) and the median overall
survival was 56.0 months. Patients who did not have expression of ERCC1, and those who had expression
of TOPO1 had signiﬁcantly better overall survival. Cox regression analysis also conﬁrmed that these two
biomarkers were signiﬁcant independent factors predicting survival (ERCC1, hazard ratio 5.51, 95%
conﬁdence interval: 2.02e14.00, p ¼ 0.001; TOPO1, hazard ratio 0.22, 95% conﬁdence interval: 0.06e0.77,
p ¼ 0.017).
Conclusion: We concluded that poor overall survival was signiﬁcantly associated with positive ERCC1 and
negative TOPO1 expression. The results might be the consequence of chemoresistance to platinum and
camptothecins, both of which are commonly used regimens in the treatment of epithelial ovarian cancer.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic
cancer among women. An estimated 1100 new cases are diagnosed
in Taiwan annually, andmore than half of them die from the disease
[1]. The high mortality rate of this disease may be partly explained
by the difﬁculty in early diagnosis and because no reliable
screening tests are available. The current management for
advanced EOC is cytoreductive surgery followed by combination
adjuvant chemotherapy, usually a platinum-based (mostlynd Gynecology, Yunlin Chang
ao Township, Yunlin County
11503, Taiwan.
bstetrics & Gynecology. Published bcarboplatin plus paclitaxel) regimen. However, around 20e30% of
patients do not respond to this regimen, the so-called platinum-
refractory group [2]. In this clinical group, agents with noncross
resistance to ﬁrst-line therapy and favorable toxicity proﬁles such
as liposomal doxorubicin or topotecan are usually chosen, however
only one ﬁfth of patients respond to the therapy [3]. Even if patients
respond to front-line chemotherapy, most will relapse and need
further treatment. The major limitation associated with the use of
cytotoxic chemotherapeutic agents is the lack of selectivity for tu-
mor cells and the associated toxicity in normal tissues. These issues
highlight the need to identify molecular biomarkers that can be
used to predict chemosensitivity and overall survival.
Several known molecular biomarkers have been studied for
predicting chemosensitivity and survival outcomes in variety of
human cancer such as ERCC1 (excision repair cross-
complementation group 1), TAU, TOPO2A (topoisomerase IIa),y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Characteristics of study participants (n ¼ 38).
Cases
n ¼ 38
%
Age at diagnosis (y)
 40 3 7.89
41e50 16 42.11
51e60 9 23.68
 61 10 26.32
Overall survival (mo)
 60 23 60.50
> 60 15 39.50
Histology
Serous 23 60.53
Mucinous 4 10.53
Endometrioid 7 18.42
Clear cell 4 10.53
FIGO stage
I 5 13.16
II 6 15.79
III 24 63.16
IV 3 7.89
Debulking surgery
Optimal 29 76.3
Suboptimal 9 23.7
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or their metabolites are also correlated with mechanism of actions
of chemotherapeutic agents that are commonly used in the treat-
ment of EOC. The main goal of the present study was to elucidate
whether the expression of these molecular biomarkers could be
used to predict therapeutic response and survival in EOC patients.
The results would be clinically helpful for physicians to identify the
patients who are most likely to beneﬁt from certain chemothera-
peutic agents.
Materials and methods
Patients enrolled
Patients with EOC were enrolled from Kaohsiung Chang Gung
Memorial Hospital, Kaohsiung, Taiwan between January 2000 and
June 2007. A total of 263 cases were identiﬁed from the cancer
registry database during this period. The study cases were
selected based on the availability of tissue for immunohisto-
chemical (IHC) staining and the chemotherapeutic agents with
which they had been treated. We selected the cases who had
received at least all of the following chemotherapeutic agents;
platinum compounds (cisplatin or carboplatin), paclitaxel, lipo-
somal doxorubicin, and topotecan, regardless of whether they
were used as adjuvant or recurrent treatment after surgery. In
total, 38 patients were included for analysis. Clinicopathological
data including demographics, staging, histological type, and
treatment course were collected from the clinical records. Anti-
tumor responses were evaluated, using the Response Criteria in
Solid Tumors (RECIST v1.1), at every course by physical exami-
nation and imaging radiography in patients with measurable
disease. Brieﬂy, a response was deﬁned as complete disappear-
ance of all measurable and assessable disease, or with a > 50%
decrease in the size of measurable lesions for at least 1 month.
Changes in the CA-125 levels based on Gynecologic Cancer Inter
Group (GCIG) criteria were also included in the deﬁnition of
response if the size of the recurrent tumor could not be assessed
[4]. A response occurred if there was at least a 50% reduction from
a pretreatment serum CA-125 and it was sustained over 28 days.
A complete response was deﬁned as the patients with CA-125
reduction below 35 U/mL. Formalin-ﬁxed, parafﬁn-embedded
tissue sections were also obtained to evaluate the expression of
the biomarkers (ERCC1, TAU, TOPO2A, TOPO1, P53, and C-MYC). This
study was approved by the Institutional Review Board of Chang
Gung Memorial Hospital.
IHC analysis and interpretation
We used a standard protocol for IHC staining of the samples,
using: ERCC1 antibodies, which are speciﬁc against the full-length
human ERCC1 protein (Neomarkers, Fremont, CA, USA); anti-TAU
monoclonal antibodies that recognize all isoforms of human TAU
protein, irrespective of phosphorylation status (clone T1029, United
States Biological, Swampscott, MA, USA); TOPO2A antibodies
SWT3D1 (Dako, Carpentaria, CA, USA) to identify topoisomerase
IIa; TOPO1 monoclonal (clone 1D6) mouse antibodies against
topoisomerase I (Novocastra, Milton Keynes, UK); P53 antibodies
(Oncogene, Boston, MA, USA); and C-MYC antibodies, which
recognize proteins of 64e67 kDa (Chemicon, Temecula, CA, USA). In
brief, 4e5-mm thick parafﬁn sections were cut and plated on
organosilane coated slides, baked overnight, and deparafﬁnized
using a DAKO LSAB-2 system (DAKO). Antigen retrieval was then
performed with boiling in citrate buffer (pH 6.0) for 10 minutes in a
microwave oven. Tumor sections were incubated for 60 minutes
with a monoclonal antibody as described above. Antibody bindingwas detected bymeans of an ABC kit with NovaRED as the substrate
(Vectastain Elite; Vector Laboratories, San Mateo, CA, USA) and
Mayers hematoxylin as the counterstain. The reactivity of the
staining was evaluated independently by two observers (C.C.H. and
J.M.L.) whowere unaware of the clinical outcomes. Brieﬂy, intensity
of ERCC1 staining was graded on a scale of 0e3þ (0, no staining; 1þ,
minimal staining; 2þ, moderate staining; and 3þ, strong staining),
the tumors with ERCC1 staining intensity scores of either 2þ in 
50% or 3þ in  10% were considered ERCC1-positive. Expression of
TAU and C-MYC were also scored on a scale of 0e3þ, the tumors
with a score of 0 or 1þ were considered negative and those with a
score of 2þ or 3þ were considered positive. TOPO2A and TOPO1
staining were considered positive if > 5% of cells showed a reddish
brown coloring of the nucleus; at least 50 cells were counted. P53
immunoreactivity was considered positive if the tumors exhibited
intense nuclear staining in > 10% of cells. All the interpretations of
staining results were based on the parameters previously estab-
lished and published [5e10].
Statistical analysis
The signiﬁcance of difference in percentagewas calculated using
c2/Fisher's exact test. Survival analysis was performed using the
KaplaneMeier method, and statistical signiﬁcance was assessed
using the log rank test. Multivariate models (Cox proportional
hazards) were applied with forward stepwise selection of cova-
riates to determine the independent prognostic factors and esti-
mate the adjusted hazard ratio (HR) of death. The length of overall
survival was deﬁned as the time between the primary surgical
treatment and death. A p value < 0.05 was required for statistical
signiﬁcance. Data processing and statistical analysis was performed
using the SPSS software package (version 17 for Windows; SPSS
Inc., Chicago, IL, USA).
Results
Table 1 shows the clinical characteristics of the 38 patients. The
mean age at diagnosis was 52.3 years, and the median overall
survival was 47.5 months (range, 10e135months). Serous histology
was the predominant cell type (60.53%), and most of the patients
(63.16%) had FIGO stage III disease at diagnosis. Optimal debulking
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the patients. All of the patients received cisplatin or carboplatin as
ﬁrst-line treatment after surgery. Thirty-three were also given
paclitaxel (86.8%), while ﬁve received cyclophosphamide (13.2%).
During the follow-up period, all of the patients had recurrent dis-
ease, and those who did not initially receive paclitaxel received it at
the ﬁrst recurrence. Liposomal doxorubicin and topotecan were
offered to all 38 patients during recurrence after the failure of
platinum and paclitaxel. According to the results of the IHC stain-
ing, the positive rates of ERCC1, TAU, TOPO2A, TOPO1, P53, and C-
MYC expression were 26.3%, 39.5%, 7.9%, 23.7%, 21.1%, and 55.3%,
respectively. Typical examples of the IHC staining of different bio-
markers are shown in Figure 1.
In KaplaneMeier survival analysis, there were no signiﬁcant
differences in 5-year overall survival rates in terms of age (<
50 years vs.  50 years), histology (serous vs. nonserous type), and
FIGO stage (I, II vs. III, IV). Patients with platinum-sensitive disease
(deﬁned as a progression-free interval for > 12 months after ﬁrst-
line platinum-based chemotherapy) had a signiﬁcantly higher 5-
year overall survival rate (67.0% vs. 37.4%, p ¼ 0.008) than those
with platinum-resistant disease. In biomarker analysis, ERCC1Figure 1. Immunohistochemical staining in representative cases. ERCC1, TAU, and C-MYC im
immunoreactivities were exclusively localized in the nucleus. P53 immunoreactivity was loexpressionwas a signiﬁcant prognostic factor for overall survival in
univariate analysis. In tumors without ERCC1 expression, the 5-year
overall survival rate (61.2%) was much higher than in the tumors
that had expression of ERCC1 (20%, p ¼ 0.012). In contrast to ERCC1,
patients who had expression of TOPO1 had a better 5-year overall
survival rate than those who did not (88.9% vs. 37.6%), although
with a marginal signiﬁcance (p ¼ 0.057). However, the expression
of TAU, TOPO2A, P53, and C-MYC were not signiﬁcantly associated
with overall survival. The results of the univariate analysis are
shown in Table 2. The KaplaneMeier estimated overall survival
curves of the patients according to the expression of the different
biomarkers are shown in Figure 2.
All of the biomarkers were included in multivariate analysis
using the Cox proportional hazards method. The results conﬁrmed
that ERCC1 and TOPO1 were independent factors predicting sur-
vival. Positive ERCC1 and TOPO1 expression were associated with
hazard ratios of 5.508 (95% conﬁdence interval, 2.023e14.997;
p ¼ 0.001) and 0.218 (95% conﬁdence interval, 0.062e0.765;
p¼ 0.017) for death, respectively. The overall survival was again not
signiﬁcantly inﬂuenced by the expression of TAU, TOPO2A, P53, and
C-MYC in multivariate analysis (Table 3).munoreactivities were localized throughout the cytoplasm, while TOPO2A and TOPO1A
calized both to the cytoplasm and nucleus.
Table 2
Univariate analysis of clinicopathological variables and biomarkers (n ¼ 38).
Cases
n ¼ 38
% Median survival (mo) 5-y survival (%) p
Age (y)
< 50 17 44.7 65.0 64.7
 50 21 55.3 42.0 34.8 0.734
Histology
Serous type 23 60.5 63.0 60.1
Nonserous type 15 39.5 40.0 33.0 0.594
FIGO Stage
I, II 11 28.9 63.0 54.5
III, IV 27 71.1 49.0 48.1 0.281
Debulking surgery
Optimal 29 76.3 49.0 43.8
Suboptimal 9 23.7 23.0 33.3 0.281
Platinum sensitivitya
Negative 22 57.9 35.0 37.4
Positive 16 42.1 78.0 67.0 0.008
Biomarker IHC staining
ERCC1
Negative 28 73.7 65.0 61.2
Positive 10 26.3 23.0 20.0 0.012
TAU
Negative 23 60.5 63.0 53.8
Positive 15 39.5 49.0 44.0 0.894
TOPO2A
Negative 35 92.1 49.0 45.1
Positive 3 7.9 63.0 50.0 0.262
TOPO1
Negative 29 76.3 42.0 37.6
Positive 9 23.7 81.0 88.9 0.057
P53
Negative 30 78.9 63.0 50.2
Positive 8 21.1 59.0 50.0 0.963
C-MYC
Negative 17 44.7 49.0 41.6
Positive 21 55.3 63.0 56.1 0.577
a Platinum-sensitivity was deﬁned as a progression-free interval for > 12months after ﬁrst-line platinum-based chemotherapy. A p-value < 0.05 was considered signiﬁcant.
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survival, we evaluated whether the expression of these two bio-
markers was associated with resistance to their corresponding
chemotherapeutic agents. ERCC1 and TOPO1 expression were
directly, but not signiﬁcantly related to resistance to platinum and
topotecan treatment, respectively. Platinum resistance was found
in 80% of the tumors with a positive ERCC1 protein expression
compared with 50% of the tumors with negative staining for ERCC1
(p > 0.05). Interestingly, patients with negative ERCC1 hadmarginal
signiﬁcant longer median progression-free survival after ﬁrst-line
chemotherapy (14 months vs. 8 months, p ¼ 0.051). Among the
patients who had an expression of TOPO1, 11.1% were responsive to
topotecan treatment comparedwith 6.9% of thosewho did not have
an expression of TOPO1 (p > 0.05). Although not signiﬁcant, these
ﬁndings translated into a signiﬁcant difference in overall survival in
both univariate andmultivariate analyses. Details of the association
between chemosensitivity and biomarker expression is shown in
Tables 4 and 5.
Discussion
We performed a retrospective study investigating ERCC1, TAU,
TOPO2A, TOPO1, P53, and C-MYC expression and their correlation
with patient survival in EOC. We used a feasible method of utilizing
well-validated antibodies in IHC analysis to determine the
expression of biomarkers in cancer tissues. We demonstrated that
immunostaining of ERCC1 and TOPO1 may be useful for predicting
survival in EOC patients after cytoreductive surgery and
chemotherapy.ERCC1 plays a role in DNA repair, and a high expression is
associated with resistance to platinum-based chemotherapy [11].
Because platinum-based chemotherapy remains the cornerstone
for treatment of EOC, the association between ERCC1 expression
and platinum sensitivity has been extensively investigated. Most
previous studies have found a positive association between ERCC1
protein expression and clinical resistance to platinum-based
chemotherapy, and they considered that the poor clinical
outcome of ERCC1-expressing tumors may be the consequence of a
poor response to platinum-containing regimens [5,12,13]. In our
study, we only found a trend towards a better clinical response to
platinum-based chemotherapy and a longer platinum-free interval
in ERCC1 negative patients. The overall median survival time was
signiﬁcantly better in ERCC1 negative EOC patients (65 months vs.
23 months), which is compatible with previous ﬁndings. However,
some recent studies did not ﬁnd any association between ERCC1
expression and platinum responsiveness and survival [14,15]. A
possible reason for this may be the difference in genotype distri-
bution of the ERCC1 gene. A common single nucleotide poly-
morphism of ERCC1 at codon 118 has been proposed to impair
translation and induce aberrant protein expression, and conse-
quently inﬂuence the response to platinum-based chemotherapy
[16]. Different ERCC1 genotypes therefore signal different responses
to chemotherapy [17]. Another possible reason may be intratumor
lymphocyte inﬁltration, which may affect the analytic results of
ERCC1 mRNA level determination [18]. In addition, the limitations
of IHC staining including the use of different antibodies, inter- or
intraobserver variations, and variable cutoff values for ERCC1 pos-
itivity may also lead to inconsistent results [19].
Figure 2. KaplaneMeier curves for overall survival and expression of studied biomarkers in the studied group of 38 ovarian cancer patients. (A) Patients who had a negative ERCC1 expression had an increased overall survival time. (B)
Patients who had a positive TOPO1 expression had an increased overall survival time. (CeF) No signiﬁcant differences in overall survival time between the patients with and without TAU, TOPO2A, P53, and C-MYC expression.
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Table 3
Multivariate analysis of biomarker expression.
Biomarker HR 95% CI p*
ERCC1 5.508 2.023e14.997 0.001
TAU 0.826 0.365e1.868 0.646
TOPO2A 1.199 0.124e11.558 0.875
TOPO1 0.218 0.062e0.765 0.017
P53 1.097 0.380e3.168 0.863
C-MYC 0.591 0.239e1.462 0.225
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
* A p value < 0.05 was considered signiﬁcant.
Table 4
Correspondence between clinical chemosensitivity and biomarker expression.
ERCC1 TOPO1
Positive Negative Positive Negative
Platinum sensitivity Sensitive 2 14 d d
Resistant 8 14 d d
Topotecan sensitivity Sensitive d d 1 2
Resistant d d 8 27
Table 5
Sensitivity, speciﬁcity, and positive and negative predictive values of ERCC1 and
TOPO1 in predicting response to their corresponding chemotherapeutic agents.
Sensitivity Speciﬁcity PPV NPV
ERCC1 (Predicting platinum sensitivity) 87.5 36.4 50.0 80.0
TOPO1 (Predicting topotecan sensitivity) 33.3 77.1 11.1 93.1
Data are presented as %.
NPV ¼ negative predictive value; PPV ¼ positive predictive value.
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study was TOPO1. The mechanismwhereby TOPO1 downregulation
produces resistance to its corresponding chemotherapeutic agent
camptothecins (topotecan or irinotecan) may be due to a reduction
of topoisomerase-DNA cleavage complexes, resulting in less DNA
damage [20]. Previous studies investigating the association be-
tween TOPO1 expression and chemotherapy responsiveness in EOC
are limited. Surowaik et al [21] demonstrated that TOPO1 over-
expression was an unfavorable prognostic factor, in contrast to
what they had expected. They explained that none of their study
cases received topotecan treatment, and therefore the application
of this agent would probably change the prognosis. Another study
investigating TOPO1 expression by measuring mRNA activity found
that the expression of TOPO1 was signiﬁcantly higher in EOC pa-
tients who did respond to irinotecan. Moreover, the accuracy of this
genetic diagnosis for chemosensitivity was 100% [22]. However, the
prognosis of the patients who had expression of TOPO1 was not
investigated. In the present study, although we found a better
survival in patients with positive TOPO1 immunostaining, there
was no association between TOPO1 expression and topotecan
responsiveness. Only three (7.9%) patients in our study cohort
responded to topotecan. Most of our patients received topotecan as
a third-line therapy or beyond, which may explain why the
response rate was low. Of these three responders, only one had
expression of TOPO1. Therefore, the poor association between
TOPO1 expression and topotecan responsiveness may be explained,
at least in part, by the small number of cases. Moreover, the ﬁrst-
line cytotoxic protocol used would lead to changes in tumor
TOPO1 expression prior to topotecan treatment. This may represent
another explanation for our results. A similar phenomenonwas also
observed between TOPO2A expression and its corresponding
doxorubicin responsiveness.The clinical signiﬁcance of P53 overexpression in patients with
EOC is uncertain. The P53 protein is a transcription factor that can
halt progression through the cell cycle or initiate apoptosis by
carcinogenic activation. It has been shown that the presence of
wild-type P53 induces sensitization to chemotherapeutic agents
[23]. Previous studies have yielded conﬂicting results, with some
revealing a correlation with far advanced disease and poor
response to chemotherapy, while our data and those of others
failed to show such associations [24,25]. This discrepancy may be
explained by differences in study populations, prognostic variables
included in multivariate analysis, and interpretation of P53 over-
expression. Furthermore, the mechanisms of chemoresistance are
complex and hard to explain on the basis of only one or two
markers.
TAU protein promotes tubulin polymerization and stabilizes
microtubules, which may render the microtubules less vulnerable
to paclitaxel [26]. Previous reports have suggested that a low TAU
expression can predict susceptibility to paclitaxel [6,27]. However,
conﬂicting results have also been reported in breast cancer studies
[28,29]. It has been reported that estrogen receptors may inﬂuence
TAU expression, and therefore TAU itself is not likely to be a direct
mechanism of taxane resistance in breast cancer [30]. To the best of
knowledge, we are the ﬁrst to report TAU expression in ovarian
cancer. We found that 39.5% of EOC patients overexpressed the TAU
protein, and we did not ﬁnd any evidence that TAU expression may
predict survival or response to paclitaxel.
C-MYC is one of the most common oncogene aberrations in
human malignancies. Its functions include regulation of the cell
cycle, proliferation, differentiation, and apoptosis. Although
downregulation of C-MYC expression has been reported to enhance
tumor cell sensitivity to platinum compounds or radiation by
activating the apoptotic program [31e34], clinical data from the
limited number of EOC studies including ours do not support such
an association [35].
There were a number of limitations to our study. First, the
sample size was too small. In order to select patients who had
received all of the chemotherapeutic agents corresponding to the
investigated biomarkers, we excluded almost 85% of our patients.
This may have biased the results. Second, we obtained tumor tis-
sues only prior to ﬁrst-line chemotherapy; the results of biomarker
expression therefore did not truly represent those just before sec-
ond- or third-line treatment because chemotherapy may alter the
expression of the biomarkers [36]. Third, we lacked fresh tissue
samples for more detailed biomarker level quantiﬁcation using
reverse transcriptionepolymerase chain reaction or Western
blotting.
In conclusion, we showed that a positive expression of ERCC1
and a negative expression of TOPO1 may be used as biomarkers to
predict poor survival in EOC patients. The results might be the
consequence of chemoresistance to platinum and camptothecins,
both of which are commonly used regimens in the treatment of
EOC. Further well-designed studies with more cases are needed for
clariﬁcation.Conﬂicts of interest
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